Quantcast

Latest Alemtuzumab Stories

New Treatment For Multiple Sclerosis Offers Promising Results
2012-11-01 09:25:28

Lawrence LeBlond for redOrbit.com - Your Universe Online A new drug to fight multiple sclerosis (MS) is showing promise as one of the “most effective” treatment options ever produced for the debilitating disease, according to UK researchers. The drug, which is used to ℠reboot´ a person´s immune system, has been shown to be effective in MS patients who have already failed to respond to the first drug with which they were treated, as well as those who have gone...

2012-01-25 12:45:20

Leukemic cutaneous T-cell lymphoma (L-CTCL) is a leukemia arising from T-cells, a type of white blood cell. This cancer can involve the skin and other organs, and patients often die within three years. Rachael A. Clark, MD, PhD, BWH assistant professor of dermatology and associate dermatologist and Thomas Kupper, MD, BWH Department of Dermatology chairman and their colleagues now report a new study that low-dose Campath (alemtuzumab) not only treats patients with L-CTCL but does so without...

2011-09-21 12:15:00

Biopharma intelligence provider will also moderate live panel on funding biopharma innovation at Prix Galien USA on September 27 in NYC. Norwood, MA (PRWEB) September 21, 2011 Over the following week, BioPharm Insight Global Editor Kimberly Ha will host two important and educational expert panels â“ one live, one online â“ focused on funding biopharma innovation and the Multiple Sclerosis drug development landscape, respectively. September 27, 2011...

2011-05-19 13:53:41

In the first head-to-head comparison of the three most common drugs used at the time of a kidney transplant to prevent organ rejection, researchers found that the least expensive drug "“ at one-half to one-fifth the price "“ is as safe and effective as the other two, according to a paper published by University of Alabama at Birmingham researchers in the May 19, 2011, issue of the New England Journal of Medicine. Based at UAB, researchers in the INTAC trial spent three years...

2010-11-02 08:13:00

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs). In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications,...

2010-08-30 08:00:00

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit...

2010-07-12 07:00:00

WALTHAM, Mass., July 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of several high-priced novel disease-modifying therapies--including the first oral agents approved for the indication--will fuel modest 3 percent annual growth in the multiple sclerosis (MS) drug market through 2019, coupled with increasing use of current and emerging monoclonal antibodies. The Pharmacor 2010...

2010-06-02 07:00:00

EXTON, Pa., June 2 /PRNewswire/ -- BioTrends released the first wave of LaunchTrends®: New Products in Multiple Sclerosis (MS), a three wave syndicated report series designed to track the uptake of Novartis's Extavia and Acorda's Ampyra. In the current wave of research, which measures success at the one month post launch mark for Ampyra and six months post launch mark for Extavia, BioTrends surveyed 82 neurologists and conducted qualitative interviews with a subset of 20...

2009-10-14 13:37:56

A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center. Such discoveries are vital in an era of skyrocketing health care costs and debate over health reform, said lead investigator Alan C. Farney, M.D., Ph.D., an associate professor of surgery in the Department of...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.